Plasma GLP1 and Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

• Conditions: Glucagon-Like Peptide 1; Coronary Angiography

• Registration Number: NCT02846168
• Lead Sponsor: Chinese PLA General Hospital

Brief Summary

The purpose of this study is to evaluate the predicting role of plasma GLP1 level on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction who undergo percutaneous coronary intervention.

Detailed Description

Acute myocardial infarction (AMI) is associated with high mortality and its prognosis differed among patients. Primary percutaneous coronary intervention (pPCI) is an effective method to treat AMI. To accurately predict adverse outcomes following pPCI in patients with AMI will help doctors develop precise therapeutic strategy in advance. At present how to predict adverse events before pPCI is still controversial. In our previous studies, the investigators found that glucagon like peptide -1 (GLP-1) can improve cardiac function in patients with AMI after PCI, other studies have reported that plasma GLP-1 levels is negatively correlated with CK-MB in patients with AMI, but the relationship between plasma GLP1 and prognosis of AMI patients after PCI has not been reported, the investigators hypothesized that plasma levels of GLP1 is associated with major adverse cardiovascular events (MACE) after pPCI. The investigators planned to evaluate the predicting role of plasma GLP1 level on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction who undergo percutaneous coronary intervention.

Study Timeline

• Study Start: 2016-04
• Study First Submitted: 2016-04-12
• Status Verified: 2016-07
• Study First Submitted QC: 2016-07-26
• Last Update Submitted: 2016-07-26
• Study First Posted: 2016-07-27
• Last Update Posted: 2016-07-27
• Primary Completion: 2017-12
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patients were eligible if they were 18 years or older and presented within 12 h from the onset of symptoms and signs of acute myocardial infarction to the catheterization laboratory.

Exclusion Criteria

• Taking drugs of GLP-1 analogue and DPP4 inhibitor
• Cancer patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
major adverse cardiovascular events (MACE) after 6 months	at 6 months

Secondary Outcome Measures

Name	Time	Method
left ventricular ejection fractions	at 3 months	measured by transthoracic echocardiography at 3 months .

Trial Locations

Locations (1)

Li Jing-Wei; 🇨🇳 Beijing, Beijing, China